Page 153 - 2023 SMOG Digital

LEVETIRACETAM C Lactation Yes (Caution) Trade Name: KEPPRA
Class / Mechanism of Action
Anticonvulsant
Causes modulation of synaptic neurotransmitter release through binding to the synaptic vesicle protein
SV2A in the brain.
Indications
Labeled Indications
• Treatment of focal (partial) onset seizures
Unlabeled:
• Traumatic brain injury, severe acute (short-term seizure prophylaxis); Status epilepticus; Craniotomy,
seizure prophylaxis; Subarachnoid hemorrhage (short-term seizure prophylaxis)
Contraindications
• Hypersensitivity to any component of the formulation
Adverse Reactions / Precautions
• May cause CNS depression
• Dermatologic reactions, possibly severe (TEN, SJS, etc)
• Hypertension has been reported in children <4 years
• Hematologic effects: Decreases in red blood cell counts, hemoglobin, hematocrit, white blood cell
counts, and neutrophils and increases in eosinophils have been observed
Dose and Administration: ADULT PEDIATRIC Always Reference BROSELOW Tape
Traumatic brain injury (severe acute) (short-term Status epilepticus, refractory: (Limited data
seizure prophylaxis): available)
• Loading dose: 20mg/kg (rounded to the nearest Infants, Children, and Adolescents:
250mg) over 60 minutes • IV: 20-60mg/kg over 15 minutes as a
• Maintenance dose: 1,000mg over 15 minutes q12hr single dose
for 7 days
Status epilepticus:
• IV: 1,000-3,000mg administered at a rate of 2-5mg/
kg/min or 40-60mg/kg as a single dose infused over
15 minutes in combination with a parenteral
benzodiazepine. Maximum dose: 4,500mg.

153